Ozempic Alternative at Just Rs 1,290: This Pharma Company to Launch an Alternative to Ozempic as the Patent Expires on March 20; Share Price Gains 3%
Join Us
Follow Us
NATCO Pharma will offer multi‑dose vials and pens of generic Semaglutide for type 2 diabetes and obesity management, marking the most affordable GLP‑1 therapy in India.
✨ AI Powered Summary
NATCO Pharma Ltd is set to launch a generic Semaglutide injection in India from March 21, 2026, at the most affordable price to date. The company is offering multi‑dose vials of the medicine with MRP starting at Rs 1,290. This launch follows the patent expiry of Ozempic and Wegovy on March 20, 2026.
The generic Semaglutide injections will be available for the treatment of type 2 diabetes as an adjunct to diet and exercise. They are also expected to be used for obesity management.
In February 2026, NATCO received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide in India. Approval covers both multi‑dose vials and pen devices based on a clinical comparison study.
Semaglutide is indicated for adults with type 2 diabetes mellitus who have insufficient control of blood glucose with diet and exercise alone.
Product Launch and Pricing
NATCO plans to launch Semaglutide injections in multi‑dose vials in strengths of 2 mg/1.5 ml, 4 mg/3 ml and 8 mg/3 ml. These will be sold under the brand names SEMANAT™ and SEMAFULL™. The multi‑dose vials will be priced at MRP Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml strengths, and Rs 1,750 per month for the 8 mg/3 ml strength.
The company will also introduce a pen device. The pen will be priced at MRP Rs 4,000 per month for 2 mg/1.5 ml, Rs 4,200 per month for 4 mg/3 ml, and Rs 4,500 per month for 8 mg/3 ml. The pen device is expected to launch in April 2026.
NATCO is the first company in India to offer generic Semaglutide in multi‑dose vials with customised syringes. The company is also offering the product for co‑marketing to third parties.
The vial form of Semaglutide is currently the most affordable glucagon‑like peptide‑1 (GLP‑1) therapy in the Indian market. It is approximately 70 per cent cheaper than the pen device and around 90 per cent cheaper than the innovator’s brand. This price advantage is expected to improve patient access to GLP‑1 therapy and support long‑term treatment adherence.
NATCO Pharma Ltd (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas.
NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.
NATCO Pharma Share Price Performance
Following the news of the launch of generic Semaglutide, the share price rose in early trade. As of March 20, 2026, at 11:47 IST, the stock was trading at Rs 966.80, up Rs 28.75 or 3.06 per cent from the previous close of Rs 938.05. The stock opened at Rs 950.00, touched a high of Rs 972.50, and a low of Rs 948.20.
Year-to-date (YTD), the stock has gained 8.26 per cent, while its one-year (1Y) performance stands at 16.40 per cent.
Disclaimer: The article is for informational purposes only and not investment advice.